Inactive Instrument

Forty Seven, Inc. Share Price

Equities

US34983P1049

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Dynamic Chart
Forty Seven, Inc.(NasdaqGS:FTSV) dropped from S&P TMI Index CI
Forty Seven, Inc.(NasdaqGS:FTSV) dropped from S&P Global BMI Index CI
Gilead Sciences, Inc. completed the acquisition of Forty Seven, Inc.. CI
Forty Seven, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019 CI
Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia CI
Certain Common Stock of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 11-MAR-2020. CI
Certain Stock Options of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 11-MAR-2020. CI
Forty Seven : Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal RE
Forty Seven : Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline RE
Gilead Sciences, Inc. entered into a definitive agreement to acquire Forty Seven, Inc. for $4.6 billion. CI
Gilead Sciences Reportedly Approaches Forty Seven with a Takeover Offer CI
Transcript : Forty Seven, Inc. - Special Call
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation CI
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab CI
Transcript : Forty Seven, Inc., Q3 2019 Earnings Call, Nov 12, 2019
More news
Managers TitleAgeSince
Founder - 31/12/13
Founder - 31/12/13
President 54 06/04/20
Members of the board TitleAgeSince
President 54 06/04/20
Director/Board Member 56 06/04/20
Director/Board Member - 06/04/20
More insiders
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company's lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company's another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW